✦ LIBER ✦

Serum CD44 levels and overall survival in patients with HER2-positive breast cancer

✍ Scribed by Jong-Min Baek; Quanri Jin; Joe Ensor; Delphine R. Boulbes; Francisco J. Esteva

Publisher: Springer US
Year: 2011
Tongue: English
Weight: 201 KB
Volume: 130
Category: Article
ISSN: 0167-6806
DOI: 10.1007/s10549-011-1691-z

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Trastuzumab prolongs overall survival in

Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer

✍ Rupert Bartsch; Andrea Rottenfusser; Catharina Wenzel; Karin Dieckmann; Ursula P 📂 Article 📅 2007 🏛 Springer US 🌐 English ⚖ 162 KB

High serum HER2 extracellular domain lev

High serum HER2 extracellular domain levels: correlation with a worse disease-free survival and overall survival in primary operable breast cancer patients

✍ Yanan Kong; Shuqin Dai; Xinhua Xie; Xiangsheng Xiao; Ning Lv; Jiaoli Guo; Laishe 📂 Article 📅 2011 🏛 Springer-Verlag 🌐 English ⚖ 385 KB

Serum HER2 levels determined by two meth

Serum HER2 levels determined by two methods in patients with metastatic breast cancer

✍ Naoki Hayashi; Seigo Nakamura; Yasuharu Tokuda; Hiroshi Yagata; Atsushi Yoshida; 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 264 KB

Trastuzumab-based neoadjuvant therapy in

Trastuzumab-based neoadjuvant therapy in patients with HER2-positive breast cancer

✍ Helena R. Chang 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 348 KB 👁 2 views

Serum immunoglobulin levels in patients

Serum immunoglobulin levels in patients with breast cancer

✍ Dr. M. Maureen Roberts; Eleanor M. Bathgate; Ann Stevenson 📂 Article 📅 1975 🏛 John Wiley and Sons 🌐 English ⚖ 250 KB 👁 2 views

Serum epidermal growth factor receptor/H

Serum epidermal growth factor receptor/HER-2 predicts poor survival in patients with metastatic breast cancer

✍ Christopher Souder; Kim Leitzel; Suhail M. Ali; Laurence Demers; Dean B. Evans; 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 205 KB 👁 2 views

## Abstract ## BACKGROUND. Epidermal growth factor receptor (EGFR, HER‐1, and __erbB__1) is overexpressed in primary breast cancer and had been identified as a poor prognostic factor. ## METHODS. Pretreatment serum EGFR levels were quantified by using an enzyme‐linked immunoadsorbent assay in a